²²⁵Ac-MTI-201, formerly ²²⁵Ac-DOTA-MC1RL, is a melanocortin 1 receptor Ligand labeled with the Alpha emitter ²²⁵Ac developed at the Moffit Cancer Center and Research Institute, Tampa FL, USA. ²²⁵Ac-MTI-201 is targeting the Melanocortin 1 receptor (MC1R) which is expressed in 94% of uveal melanoma metastases. This current application seeks to characterize a potential companion diagnostic Imaging agent ⁶⁷Ga-DOTA-MTI-201 in preclinical models.

Target/Mechanism: Melanocortin-1

Carrier/Ligand: Fab

Radiation Type: Alpha particle (α)